VRTX Stock Recent News

The stock market has been a generous vehicle for building investor wealth through the years even though ups and downs are inevitable. If you stay invested in the stock market for decades, gradually and regularly building out a diverse portfolio, you will likely encounter your share of bull as well as bear markets.

Get a deeper insight into the potential performance of Vertex (VRTX) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Vertex Pharmaceuticals (VRTX) closed at $468.41 in the latest trading session, marking a +1.64% move from the prior day.

VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and Alyftrek and Journavx launches.

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex Pharmaceuticals (VRTX -0.57%) has been a terrific stock to own over the past decade. The stock has outperformed the market over this period, thanks to consistent financial results and excellent innovative capabilities.

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $476.95, signifying a +1.45% move from its prior day's close.

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially positive data readouts.

For decades, Jim McKay introduced ABC's Wide World of Sports with a memorable phrase, "The thrill of victory, and the agony of defeat." McKay's words could apply to many investors in the first half of this year.